Detección inmunohistoquímica de la mutación BRAF V600E en el carcinoma papilar de tiroides. Evaluación frente a la reacción en cadena de la polimerasa en tiempo real

Fano, Miguel Paja; Olano, Aitziber Ugalde; Thomas, Elena Fuertes; Alday, Amelia Oleaga

doi:10.1016/j.endinu.2016.12.004

Cited by 12 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, as a universal explanation, one can consider the heterogeneity of the tumor and the fact that the immunohistochemically analyzed tissue was not exactly the same tissue fragment examined by RT-PCR. Finally, the expression on mRNA and protein levels was not always synchronized ( 23 , 24 ).…”

Section: Discussionmentioning

confidence: 99%

Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly

Mendes

Haag

Trott

et al. 2018

Braz J Med Biol Res

View full text Add to dashboard Cite

Pituitary adenomas account for 10–15% of primary intracranial tumors. Growth hormone (GH)-secreting adenomas account for 13% of all pituitary adenomas and cause acromegaly. These tumors can be aggressive, invade surrounding structures and are highly recurrent. The objective of this study was to evaluate E-cadherin, Slug and neural cell adhesion molecule (NCAM) expression in GH-secreting pituitary adenomas and its relationship to tumor invasiveness. A cross–sectional study of patients who underwent hypophysectomy due to GH-secreting pituitary adenoma from April 2007 to December 2014 was carried out. The medical records were reviewed to collect clinical data. Immediately after surgery, tumor samples were frozen in liquid nitrogen and stored in a biofreezer at –80°C for assessment of E-cadherin 1 (CDH1), SLUG (SNAI2), and NCAM (NCAM1) by real-time PCR. The samples were fixed in formalin and embedded in paraffin for immunohistochemical analysis of E-cadherin and NCAM. Thirty-five patients with acromegaly were included in the study. Of these, 65.7% had invasive tumors. Immunohistochemically, E-cadherin was expressed in 96.7% of patients, and NCAM in 80% of patients. There was no statistically significant relationship between tumor grade or invasiveness and immunohistochemical expression of these markers. Regarding gene expression, 50% of cases expressed CDH1, none expressed SNAI2, and 53.3% expressed NCAM1. There was no statistically significant relationship between tumor grade or invasiveness and gene expression of CDH1, SNAI2, and NCAM1. The absence of Slug overexpression and of E-cadherin and NCAM suppression suggests that expression of these markers is not associated with tumor invasiveness in GH-secreting pituitary adenomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly

Mendes

Haag

Trott

et al. 2018

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…From the literature review, possible explanations for VE1 IHC false negatives could be technical (suboptimal fixation condition, tissue ischemia in perinecrotic zones) [38,48] or functional (loss of expression of mutation antigen, presence of additional mutation preventing translocation of mutated mRNA into functional protein) [43]. As it could be learned from our series, tumors with VE1 immunoreactivity but negative results of Sanger sequencing represented false negative sequencing but not false positive IHC.…”

Section: Discussionmentioning

confidence: 84%

“…Although Sanger sequencing has been widely acknowledged as the standard technique for detection of point mutation, from the literature review, we found out that the discordant rates are much higher when using Sanger sequencing (7-23%) to validate the performance of VE1 IHC [20,23,25,31,35,[38][39][40], than using a more sensitive molecular method, such as real-time PCR (0.1-8%) [19,22,23,[41][42][43][44][45]. Several groups achieved a discordance rate of < 2% when VE1 immunostaining was compared to real-time PCR [22,43]. Jung et al used RNA-ISH, and their discordant rate was 1.9% [41].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer

Choden

Keelawat

Jung

et al. 2020

Cancers

View full text Add to dashboard Cite

Detection of BRAFV600E is useful for making diagnosis and risk stratification of papillary thyroid carcinoma (PTC). Molecular testing, however, is not always available for routine clinical use. To assess the clinical utility and reliability of VE1 immunohistochemistry (IHC) for detecting BRAFV600E mutation in PTC, VE1 IHC was performed on the tissue microarrays of 514 patients with PTC and was compared with Sanger sequencing results. Of 514 PTC cases, 433 (84.2%) were positive for VE1 expression. Among 6 discordant cases between VE1 IHC and Sanger sequencing, 3 initial VE1-false negative cases turned out to be true false negative on repeat testing, and 3 VE1-false positive cases showed BRAFV600E mutation using digital PCR analysis. PTCs with low variant allele fraction were positive for VE1 IHC but were not detected using sequencing. VE1 IHC showed 99.3% sensitivity, 100% specificity, 100% positive predictive value, and 96.4% negative predictive value. The BRAFV600E mutation was significantly associated with older age, multifocality, extrathyroidal extension, lymph node metastasis, and advanced tumor stage. In conclusion, VE1 IHC is a reliable method for detecting BRAFV600E mutation in PTC specimens.

show abstract

Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma

Smith

Williams

Stewart

et al. 2018

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

Detección inmunohistoquímica de la mutación BRAF V600E en el carcinoma papilar de tiroides. Evaluación frente a la reacción en cadena de la polimerasa en tiempo real

Cited by 12 publications

References 27 publications

Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly

Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer

Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma

Contact Info

Product

Resources

About